I expect a 3x increase from the 40cent CR in speculation leading up to the Phase 3 trial during March 2025 (6 months away) waiting for April and with P3 readout success, a potential 6x to 16x increase by August 2026 on successful commercialization (US$5B company?). And of course, real but significantly smaller possibility of a 0x full loss of capital outcome.
Opthea Q&A Sep 2024 Update, page-32
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
87.3¢ |
Change
-0.008(0.85%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 88.0¢ | 88.0¢ | 86.5¢ | $874.9K | 1.000M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 129723 | 87.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.5¢ | 23602 | 38 |
View Market Depth
| Last trade - 11.51am 09/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |